^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MSLN positive

i
Other names: MSLN, CAK1, MPF, Mesothelin
Entrez ID:
Related biomarkers:
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/16/2024
Initiation :
12/09/2019
Primary completion :
01/31/2025
Completion :
01/31/2025
MSLN
|
MSLN expression • MSLN positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/16/2024
Initiation :
10/12/2018
Primary completion :
10/21/2024
Completion :
10/21/2024
MSLN
|
MSLN positive
|
Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Phase 1/2
RemeGen Co., Ltd.
Recruiting
Last update posted :
04/30/2024
Initiation :
07/19/2023
Primary completion :
05/01/2025
Completion :
12/01/2025
MSLN
|
MSLN positive
|
Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
Phase 1/2
TCR2 Therapeutics
Active, not recruiting
Last update posted :
03/06/2024
Initiation :
04/15/2019
Primary completion :
11/02/2028
Completion :
11/02/2028
MSLN
|
MSLN expression • MSLN positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
Phase 1/2
TCR2 Therapeutics
Active, not recruiting
Last update posted :
03/06/2024
Initiation :
06/21/2022
Primary completion :
10/30/2028
Completion :
10/30/2028
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • TC-510
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
02/01/2024
Initiation :
02/06/2024
Primary completion :
12/18/2024
Completion :
12/18/2024
MSLN
|
MSLN expression • MSLN positive
|
LMB-100
Phase 1
Second Affiliated Hospital of Guangzhou Medical...
Recruiting
Last update posted :
11/15/2023
Initiation :
03/10/2023
Primary completion :
03/10/2026
Completion :
03/10/2033
MSLN
|
MSLN expression • MSLN positive
|
Mesothelin-CAR-T
Phase N/A
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
10/03/2023
Initiation :
03/01/2011
Primary completion :
09/01/2024
Completion :
09/01/2024
MSLN
|
MSLN expression • MSLN positive
Phase 1
Amgen
Completed
Last update posted :
09/22/2023
Initiation :
04/29/2021
Primary completion :
06/05/2023
Completion :
06/05/2023
MSLN
|
MSLN expression • MSLN positive
|
inezetamab (AMG 994) • zeluvalimab (AMG 404)
Phase 1
First Affiliated Hospital of Shantou University...
Not yet recruiting
Last update posted :
01/16/2023
Initiation :
02/01/2023
Primary completion :
02/01/2024
Completion :
06/01/2024
HER-2 • ER • PGR • MSLN
|
HER-2 negative • ER negative • MSLN positive • PGR negative
|
SZ011
Phase 1
Tongji Hospital
Recruiting
Last update posted :
04/27/2022
Initiation :
01/12/2022
Primary completion :
11/01/2023
Completion :
11/01/2036
MSLN
|
MSLN positive
|
RD133
Phase 1
Peking University
Not yet recruiting
Last update posted :
04/25/2022
Initiation :
04/14/2022
Primary completion :
10/14/2024
Completion :
02/01/2026
EGFR • ALK • MET • ROS1 • MSLN
|
ALK positive • EGFR positive • EGFR negative • MSLN positive
|
YTS105
Phase 1
The First Affiliated Hospital with Nanjing Medi...
Recruiting
Last update posted :
12/21/2021
Initiation :
01/01/2022
Primary completion :
01/01/2024
Completion :
01/01/2037
MSLN
|
MSLN positive
|
RD133
Phase 1
Ruijin Hospital
Recruiting
Last update posted :
09/17/2021
Initiation :
10/01/2021
Primary completion :
01/09/2022
Completion :
07/09/2022
MSLN
|
MSLN positive
|
cyclophosphamide • MSLN CAR-T • UCLM802
Phase 1
Shanghai 6th People's Hospital
Recruiting
Last update posted :
08/10/2021
Initiation :
08/16/2019
Primary completion :
01/01/2023
Completion :
01/01/2023
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
02/04/2021
Initiation :
09/01/2019
Primary completion :
05/01/2021
Completion :
12/01/2021
HLA-A • MSLN • CTAG1B
|
HLA-A*02:01 • MSLN positive • HLA-A positive
|
cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 1/2
Xinqiao Hospital of Chongqing
Not yet recruiting
Last update posted :
11/13/2020
Initiation :
12/01/2020
Primary completion :
12/31/2022
Completion :
12/31/2023
MSLN
|
MSLN positive
|
cyclophosphamide • TC-A101
Phase 1
Chinese PLA General Hospital
Unknown status
Last update posted :
08/10/2020
Initiation :
03/19/2018
Primary completion :
10/30/2020
Completion :
12/30/2020
MSLN
|
MSLN positive
|
GC008t • MPTK-CAR-T cells • MSLN CAR-T
Phase 1/2
Second Affiliated Hospital, School of Medicine,...
Recruiting
Last update posted :
04/16/2019
Initiation :
04/20/2019
Primary completion :
04/20/2022
Completion :
04/20/2023
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV
Phase 1
Zhejiang University
Unknown status
Last update posted :
04/10/2019
Initiation :
04/10/2019
Primary completion :
10/01/2021
Completion :
04/01/2022
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells
Phase 1
Allife Medical Science and Technology Co., Ltd.
Unknown status
Last update posted :
01/31/2019
Initiation :
03/01/2019
Primary completion :
11/01/2020
Completion :
11/01/2021
PD-L1 • PD-1 • MSLN
|
MSLN expression • MSLN positive
|
MSLN CAR-T • anti-Mesothelin CAR NK Cells
Phase 1
Chinese PLA General Hospital
Unknown status
Last update posted :
11/20/2018
Initiation :
11/01/2018
Primary completion :
11/01/2019
Completion :
05/01/2020
MSLN
|
MSLN positive
|
paclitaxel • cyclophosphamide • GC008t
Phase 1/2
Ningbo Cancer Hospital
Unknown status
Last update posted :
01/24/2017
Initiation :
02/15/2017
Primary completion :
12/01/2018
Completion :
02/01/2019
MSLN
|
MSLN positive
Phase 1
China Meitan General Hospital
Unknown status
Last update posted :
10/12/2016
Initiation :
08/01/2016
Primary completion :
08/01/2018
Completion :
08/01/2019
MSLN
|
MSLN positive
|
cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells
Phase 1
Eisai Co., Ltd.
Completed
Last update posted :
01/21/2016
Initiation :
11/01/2009
Primary completion :
05/01/2012
Completion :
02/01/2013
MSLN
|
MSLN positive
|
amatuximab (MORAb-009)
Phase 1
Chinese PLA General Hospital
Unknown status
Last update posted :
10/20/2015
Initiation :
10/01/2015
Primary completion :
11/01/2017
Completion :
11/01/2018
MSLN
|
MSLN positive
Phase 1
Morphotek
Completed
Last update posted :
07/17/2014
Initiation :
05/01/2006
Primary completion :
09/01/2008
Completion :
09/01/2008
MSLN
|
MSLN expression • MSLN positive
|
amatuximab (MORAb-009)